Skip to main content
Premium Trial:

Request an Annual Quote

FDA Approves Dako's HER2 IQFISH Assay

NEW YORK (GenomeWeb News) – Dako today announced that the US Food and Drug Administration has approved its HER2 IQFISH pharmDx assay for marketing in the US.

HER2 IQFISH pharmDx is a fluorescence in situ hybridization assay based on Dako's "instant quality in situ hybridization" buffer chemistry, and according to the firm, the assay will reduce the cancer diagnosis turnaround time to three-and-a-half hours from the current two days.

The assay is the first product based on the Dako IQISH technology to receive FDA approval and can offer laboratories greater speed as well as accuracy in identifying HER2 gene status, Dako said.

HER2-positive breast cancer tends to be especially aggressive and less responsive to hormone treatment, it said. As a result, specifically targeted treatments are sometimes required.

"HER2 IQFISH pharmDx improves the workflow in the pathology laboratory and is a valuable aid in assessing patients for whom trastuzumab treatment is being considered," said David Hardisson from the department of pathology at the University Hospital La Paz, School of Medicine, Autonomous University of Madrid.

HER2 IQFISH pharmDx is CE marked and has been available in parts of Europe for the past year, Dako noted.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.